Mao Y - Search Results

1

Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.

Jin ZQ, Hao J, Yang X, He JH, Liang J, Yuan JW, Mao Y, Liu D, Cao R, Wu XZ, Li X, Chen D. Jin ZQ, et al. Among authors: mao y. Oncol Rep. 2018 Oct;40(4):2127-2136. doi: 10.3892/or.2018.6629. Epub 2018 Aug 6. Oncol Rep. 2018. PMID: 30106443

2

bFGF Promotes Migration and Induces Cancer-Associated Fibroblast Differentiation of Mouse Bone Mesenchymal Stem Cells to Promote Tumor Growth.

Yang X, Hao J, Mao Y, Jin ZQ, Cao R, Zhu CH, Liu XH, Liu C, Ding XL, Wang XD, Chen D, Wu XZ. Yang X, et al. Among authors: mao y. Stem Cells Dev. 2016 Nov 1;25(21):1629-1639. doi: 10.1089/scd.2016.0217. Epub 2016 Sep 12. Stem Cells Dev. 2016. PMID: 27484709

3

Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients.

Mao Y, Hao J, Jin ZQ, Niu YY, Yang X, Liu D, Cao R, Wu XZ. Mao Y, et al. Oncotarget. 2017 Apr 18;8(16):27007-27021. doi: 10.18632/oncotarget.15351. Oncotarget. 2017. PMID: 28212580 Free PMC article.

4

A seven-lncRNA signature predicts overall survival in esophageal squamous cell carcinoma.

Mao Y, Fu Z, Zhang Y, Dong L, Zhang Y, Zhang Q, Li X, Liu J. Mao Y, et al. Sci Rep. 2018 Jun 11;8(1):8823. doi: 10.1038/s41598-018-27307-2. Sci Rep. 2018. PMID: 29891973 Free PMC article.

5

Antiestrogenic Activity of the Xi-Huang Formula for Breast Cancer by Targeting the Estrogen Receptor α.

Hao J, Jin Z, Zhu H, Liu X, Mao Y, Yang X, Gao L, Liu D, Chen D, Wu X. Hao J, et al. Among authors: mao y. Cell Physiol Biochem. 2018;47(6):2199-2215. doi: 10.1159/000491533. Epub 2018 Jul 5. Cell Physiol Biochem. 2018. PMID: 29975948 Free article.

6

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis.

Li SJ, Hao J, Mao Y, Si YL. Li SJ, et al. Among authors: mao y. Turk J Haematol. 2020 Feb 20;37(1):13-19. doi: 10.4274/tjh.galenos.2019.2019.0128. Epub 2019 Aug 29. Turk J Haematol. 2020. PMID: 31464119 Free PMC article.

7

MiR-1290 promotes cancer progression by targeting nuclear factor I/X(NFIX) in esophageal squamous cell carcinoma (ESCC).

Mao Y, Liu J, Zhang D, Li B. Mao Y, et al. Biomed Pharmacother. 2015 Dec;76:82-93. doi: 10.1016/j.biopha.2015.10.005. Epub 2015 Nov 10. Biomed Pharmacother. 2015. Retraction in: Biomed Pharmacother. 2024 Feb;171:116189. doi: 10.1016/j.biopha.2024.116189 PMID: 26653554 Retracted.

8

MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1.

Mao Y, Li L, Liu J, Wang L, Zhou Y. Mao Y, et al. Oncotarget. 2016 Aug 9;7(32):51223-51236. doi: 10.18632/oncotarget.9981. Oncotarget. 2016. PMID: 27323412 Free PMC article.

9

miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma.

Mao Y, Liu J, Zhang D, Li B. Mao Y, et al. Tumour Biol. 2016 Jul;37(7):9009-22. doi: 10.1007/s13277-015-4760-9. Epub 2016 Jan 13. Tumour Biol. 2016. PMID: 26758433

10

RETRACTED: MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma.

Liu J, Mao Y, Zhang D, Hao S, Zhang Z, Li Z, Li B. Liu J, et al. Among authors: mao y. Cancer Lett. 2016 Apr 1;373(1):97-108. doi: 10.1016/j.canlet.2016.01.023. Epub 2016 Jan 21. Cancer Lett. 2016. Retraction in: Cancer Lett. 2018 May 28;422:133. doi: 10.1016/j.canlet.2018.03.021 PMID: 26806810 Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,597 results

Search Page

Filters